News
Please, enter cell line, author or any other phrase or word you would like to search for.
Insider Acquisitions in Phase Holographic Imaging
CEO Patrik Eschricht, chairman Peter Egelberg and deputy board member Ann Christine Egelberg has recently acquired additional holdings in Phase Holographic Imaging.
PHI enters into underwriting commitment with Altium in ongoing exercise of TO 3 warrants
PHI announces that the Company’s largest shareholder Altium and PHI has agreed on an underwriting commitment free-of-charge in the ongoing exercise of warrants of series TO 3.
Altium S.A. exercised all their obtained warrants TO 3
PHI announces that Altium S.A. exercised all their obtained warrants TO 3.
The exercise period for warrants of series TO 3 begins today
PHI announces that the exercise period for warrants of series TO 3 begins today.
The subscription price for warrants of series TO 3 has been set at SEK 3.78 per share
PHI announces that the subscription price for warrants of series TO 3 has been set at SEK 3.78 per share.
BioStock: PHI´s CEO comments on latest advancements
BioStock reached out to PHI´s CEO, Patrik Eschricht, to learn more about the visions moving forward.
Interim Report 3 2022/23
Sales have continued to grow, with significantly higher cost efficiency. As a result, rolling 12-month sales gained to its highest level ever.
Clarification Regarding Potential Collaborations
Thi information is provided to mitigate any misinterpretation of the information unintentionally made publicly after a PHI presentation at a CERN Knowledge Transfer Seminar held on March 27, 2023.
Notice that Interim Report 3 2022/23 will be published already on March 28, 2023
PHI changes the date for publication of Interim Report 3 2022/23 to March 28, 2023.
PHI creates a subsidiary for the anticipated EU patent concerning synthetic antibodies
PHI has decided to create a dedicated subsidiary to house the synthetic antibody patent family and facilitate its business potential.